Here are three things to know
1. The drug, Steglatro, is a SGLT2 inhibitor, which works by causing patients with Type 2 diabetes to rid glucose through their urine.
2. The oral drug enters the market as a competitor to AstraZeneca’s Farxiga, Johnson & Johnson’s Invokana and Eli Lilly and Boehringer Ingelheim’s Jardiance.
3. The FDA granted Steglatro approval as both a single-therapy or a fixed-dose combination therapy with Merck’s already-approved diabetes drug Januvia or metformin, which is an older generic version of a diabetes drug.
More articles on supply chain:
6 must-reads for supply chain leaders this week
France officials fine J&J $30M for allegedly restricting access to generic versions of its pain patch
Pfizer authorizes $10B share buyback
